With these promising data showing that MK-0616 reduced LDL-C levels by up to 60.9%, MK-0616 should be further studied for its potential as a daily oral medicine.” “These data reinforce our confidence that MK-0616 could become the first ora...
本文分子为Merck公司Ⅱ期临床环肽药物MK-0616 的结构类似物。拟肽类化合物以酰胺键连接各个片段,故在逆合成时通常作断键优选。多肽化合物通过氨基酸的C/N端单保护成肽键后脱保护如此反复而得,肽键构建其在方法上没有太多花样;但大环化合物成环却很有难度。 阅读本文可知文章写作以实验操作和处理为描述之重,例如加...
【医学同传前沿】本周三个Merck/MSD的临床试验研究者会议同传,涉及的药物有MK-6024、MK-8521、MK-1462、Sotorasib、Adagrasib、LY3537982、Pembrolizumab、GDC-6036 (divarasib)、MK-1084、Statin、Bempedoic Acid、MK-0616,核心药物MK-6024、MK-1084、MK-0616,药物类别KRAS G12C抑制剂、GLP-1-based Co-agonists...
3.口服PCSK9抑制剂预计8月就启动3期:We are advancing our broad cardiovascular program. Enrollment in Phase 3 trials for MK-0616, our oral PCSK9 inhibitor, is anticipated to start later this month. 4. 科伦的TROP2ADC在准备开肺癌3期:We are advancing the broad clinical development program for th...
Now, Merck has presented data at the American Heart Association Meeting on its experimental drug MK-0616, which is also a PCSK9 inhibitor, according to BioSpace. Repatha and Praluent may face a big challenge if Merck is able to bring its drug to the finishing line, which is now...
CTR20242351帕博利珠单抗联合或不联合MK-2870治疗未达到pCR的可切除NSCLC受试者查看非小细胞肺癌进行中(招募中)3期默沙东研发(中国)有限公司北京大学人民医院;北京大学人民医院2024-07-02 CTR20242333MK-0616在高胆固醇血症成人中的开放标签扩展研究查看高胆固醇血症进行中(尚未招募)3期不适用/ 默沙东研发(中国)有限公...
2023年,默沙东针对Keytruda新开了多项联合治疗III期临床研究,其中包括与肿瘤mRNA疫苗V940(mRNA-4157)联合治疗非小细胞肺癌(NSCLC)的两项研究,以及与TROP2 ADC新药MK-2870(从科伦博泰引进)联合一线治疗NSCLC的关键III期研究。除了继续挖掘Keytruda与其他疗法联合的治疗潜力,默沙东还计划通过增补肿瘤产品管线进一步丰富产品群...
year ago. At the American College of Cardiology conference, we will present data from the STELLAR trial evaluating sotatercept in pulmonary arterial hypertension and from the Phase 2 trial of MK-0616, our oral PCSK9 inhibitor, and we will also host an investor event to discuss these programs...
Merck will present results from the Phase 3 STELLAR study evaluating investigational sotatercept for the treatment of patients with pulmonary arterial hypertension, and from the Phase 2 study evaluating MK-0616, the company’s investigational oral macrocyclic peptide PCSK9 inhibitor for the treatment of...
(MK-7339) Oncology Non-small cell lung cancer Small cell lung cancer Advanced solid tumors Small molecule MK-0616 Cardiovascular Hypercholesterolemia Peptide MK-1084 Oncology KRAS G12C-mutated non-small cell lung cancer Small molecule MK-2060 ...